Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Interpace Diagnostics Group Inc (NASDAQ:IDXG)

1.54
Delayed Data
As of 4:00pm ET
 -0.04 / -2.53%
Today’s Change
0.70
Today|||52-Week Range
19.80
-65.00%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$35.0M

Company Description

Interpace Diagnostics Group, Inc. engages in the development and commercialization of molecular diagnostic test. It focuses on early detection high potential progresses to cancer. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Contact Information

Interpace Diagnostics Group, Inc.
Morris Corporate Center 1, Bldg. C
Parsippany New Jersey 07054
P:(855) 776-6419
Investor Relations:

Employees

Shareholders

Other institutional8.00%
Mutual fund holders0.52%
Individual stakeholders0.24%

Top Executives

Jack E. StoverPresident, Chief Executive Officer & Director
Glenn GershonSenior Vice President-Operations
James EarlyChief Financial Officer
Sydney D. FinkelsteinChief Scientific Officer
Sara A. JacksonVice President-Clinical Development